02662nas a2200397   4500000000100000008004100001260003400042653005700076653002100133653002800154100001300182700002000195700001400215700001200229700001400241700001400255700001200269700001300281700001100294700001500305700001200320700001100332700001400343700001600357700001100373700001000384700001500394700001700409700001200426245018000438856009200618300001300710490000700723520150900730022002502239       2023                            d  bOxford University Press (OUP)10aPublic Health, Environmental and Occupational Health10aGeneral Medicine10aHealth (social science)1 aAtekem K1 aHarding-Esch EM1 aMartin DL1 aDowns P1 aPalmer SL1 aKaboré A1 aKelly M1 aBovary A1 aSarr A1 aNguessan K1 aJames F1 aGwyn S1 aWickens K1 aBakhtiari A1 aBoyd S1 aAba A1 aSenyonjo L1 aCourtright P1 aMeite A00aHigh prevalence of trachomatous inflammation–follicular with no trachomatous trichiasis: can alternative indicators explain the epidemiology of trachoma in Côte d’Ivoire?  uhttps://academic.oup.com/inthealth/article-pdf/15/Supplement_2/ii3/53979179/ihad069.pdf  aii3-ii110 v153 a<p>Baseline trachoma surveys in Côte d'Ivoire (2019) identified seven evaluation units (EUs) with a trachomatous inflammation–follicular (TF) prevalence ≥10%, but a trachomatous trichiasis (TT) prevalence in individuals ≥15&nbsp;y of age below the elimination threshold (0.2%). Two of these EUs, Bondoukou 1 and Bangolo 2, were selected for a follow-up survey to understand the epidemiology of trachoma using additional indicators of Chlamydia trachomatis infection (DNA from conjunctival swabs) and exposure (anti-Pgp3 and Ct694 antibodies from dried blood spots [DBSs]). A two-stage cluster sampling methodology was used to select villages and households. All individuals 1–9&nbsp;y of age from each selected household were recruited, graded for trachoma and had a conjunctival swab and DBS collected. Conjunctival swabs and DBSs were tested using Cepheid GeneXpert and a multiplex bead assay, respectively. The age-adjusted TF and infection prevalence in 1- to 9-year-olds was &amp;lt;1% and &amp;lt;0.3% in both EUs. Age-adjusted seroprevalence was 5.3% (95% confidence interval [CI] 1.5 to 15.6) in Bondoukou 1 and 8.2% (95% CI 4.3 to 13.7) in Bangolo 2. The seroconversion rate for Pgp3 was low, at 1.23 seroconversions/100 children/year (95% CI 0.78 to 1.75) in Bondoukou 1 and 1.91 (95% CI 1.58 to 2.24) in Bangolo 2. Similar results were seen for CT694. These infection, antibody and clinical data provide strong evidence that trachoma is not a public health problem in either EU.</p>
  a1876-3413, 1876-3405